187 related articles for article (PubMed ID: 32251515)
21. Hypoxia, Hypoxia-inducible Transcription Factors, and Renal Cancer.
Schödel J; Grampp S; Maher ER; Moch H; Ratcliffe PJ; Russo P; Mole DR
Eur Urol; 2016 Apr; 69(4):646-657. PubMed ID: 26298207
[TBL] [Abstract][Full Text] [Related]
22. Silencing of epidermal growth factor receptor suppresses hypoxia-inducible factor-2-driven VHL-/- renal cancer.
Smith K; Gunaratnam L; Morley M; Franovic A; Mekhail K; Lee S
Cancer Res; 2005 Jun; 65(12):5221-30. PubMed ID: 15958567
[TBL] [Abstract][Full Text] [Related]
23. Inhibition of the hypoxia-inducible factor pathway by a G-quadruplex binding small molecule.
Welsh SJ; Dale AG; Lombardo CM; Valentine H; de la Fuente M; Schatzlein A; Neidle S
Sci Rep; 2013 Sep; 3():2799. PubMed ID: 24165797
[TBL] [Abstract][Full Text] [Related]
24. BRDT is a novel regulator of eIF4EBP1 in renal cell carcinoma.
Wan P; Chen Z; Zhong W; Jiang H; Huang Z; Peng D; He Q; Chen N
Oncol Rep; 2020 Dec; 44(6):2475-2486. PubMed ID: 33125143
[TBL] [Abstract][Full Text] [Related]
25. HepaCAM Regulates Warburg Effect of Renal Cell Carcinoma via HIF-1α/NF-κB Signaling Pathway.
Fan Y; Ou L; Fan J; Li L; Wu X; Luo C; Gao Y; Niu L
Urology; 2019 May; 127():61-67. PubMed ID: 30528714
[TBL] [Abstract][Full Text] [Related]
26. Onconeuronal cerebellar degeneration-related antigen, Cdr2, is strongly expressed in papillary renal cell carcinoma and leads to attenuated hypoxic response.
Balamurugan K; Luu VD; Kaufmann MR; Hofmann VS; Boysen G; Barth S; Bordoli MR; Stiehl DP; Moch H; Schraml P; Wenger RH; Camenisch G
Oncogene; 2009 Sep; 28(37):3274-85. PubMed ID: 19581925
[TBL] [Abstract][Full Text] [Related]
27. CD133 expression in renal cell carcinoma (RCC) is correlated with nuclear hypoxia-inducing factor 1α (HIF-1α).
Sun C; Song H; Zhang H; Hou C; Zhai T; Huang L; Zhang L
J Cancer Res Clin Oncol; 2012 Oct; 138(10):1619-24. PubMed ID: 22614155
[TBL] [Abstract][Full Text] [Related]
28. MicroRNA-99a induces G1-phase cell cycle arrest and suppresses tumorigenicity in renal cell carcinoma.
Cui L; Zhou H; Zhao H; Zhou Y; Xu R; Xu X; Zheng L; Xue Z; Xia W; Zhang B; Ding T; Cao Y; Tian Z; Shi Q; He X
BMC Cancer; 2012 Nov; 12():546. PubMed ID: 23173671
[TBL] [Abstract][Full Text] [Related]
29. Biochemical and Epigenetic Insights into L-2-Hydroxyglutarate, a Potential Therapeutic Target in Renal Cancer.
Shelar S; Shim EH; Brinkley GJ; Kundu A; Carobbio F; Poston T; Tan J; Parekh V; Benson D; Crossman DK; Buckhaults PJ; Rakheja D; Kirkman R; Sato Y; Ogawa S; Dutta S; Velu SE; Emberley E; Pan A; Chen J; Huang T; Absher D; Becker A; Kunick C; Sudarshan S
Clin Cancer Res; 2018 Dec; 24(24):6433-6446. PubMed ID: 30108105
[TBL] [Abstract][Full Text] [Related]
30. DNA Methylation Signature Reveals Cell Ontogeny of Renal Cell Carcinomas.
Malouf GG; Su X; Zhang J; Creighton CJ; Ho TH; Lu Y; Raynal NJ; Karam JA; Tamboli P; Allanick F; Mouawad R; Spano JP; Khayat D; Wood CG; Jelinek J; Tannir NM
Clin Cancer Res; 2016 Dec; 22(24):6236-6246. PubMed ID: 27256309
[TBL] [Abstract][Full Text] [Related]
31. Genome-wide gene expression profiles of clear cell renal cell carcinoma: identification of molecular targets for treatment of renal cell carcinoma.
Hirota E; Yan L; Tsunoda T; Ashida S; Fujime M; Shuin T; Miki T; Nakamura Y; Katagiri T
Int J Oncol; 2006 Oct; 29(4):799-827. PubMed ID: 16964377
[TBL] [Abstract][Full Text] [Related]
32. MUC1, a new hypoxia inducible factor target gene, is an actor in clear renal cell carcinoma tumor progression.
Aubert S; Fauquette V; Hémon B; Lepoivre R; Briez N; Bernard D; Van Seuningen I; Leroy X; Perrais M
Cancer Res; 2009 Jul; 69(14):5707-15. PubMed ID: 19549898
[TBL] [Abstract][Full Text] [Related]
33. LHX6 acts as a novel potential tumour suppressor with epigenetic inactivation in lung cancer.
Liu WB; Jiang X; Han F; Li YH; Chen HQ; Liu Y; Cao J; Liu JY
Cell Death Dis; 2013 Oct; 4(10):e882. PubMed ID: 24157876
[TBL] [Abstract][Full Text] [Related]
34. Functional and epigenetic characterization of the KRT19 gene in renal cell neoplasms.
Paiva F; Duarte-Pereira S; Costa VL; Ramalho-Carvalho J; Patrício P; Ribeiro FR; Lobo F; Oliveira J; Jerónimo C; Henrique R
DNA Cell Biol; 2011 Feb; 30(2):85-90. PubMed ID: 20874491
[TBL] [Abstract][Full Text] [Related]
35. VHL inactivation without hypoxia is sufficient to achieve genome hypermethylation.
Artemov AV; Zhigalova N; Zhenilo S; Mazur AM; Prokhortchouk EB
Sci Rep; 2018 Jul; 8(1):10667. PubMed ID: 30006568
[TBL] [Abstract][Full Text] [Related]
36. LncRNA HOTAIR regulates HIF-1α/AXL signaling through inhibition of miR-217 in renal cell carcinoma.
Hong Q; Li O; Zheng W; Xiao WZ; Zhang L; Wu D; Cai GY; He JC; Chen XM
Cell Death Dis; 2017 May; 8(5):e2772. PubMed ID: 28492542
[TBL] [Abstract][Full Text] [Related]
37. Metabolic Modulation of Clear-cell Renal Cell Carcinoma with Dichloroacetate, an Inhibitor of Pyruvate Dehydrogenase Kinase.
Kinnaird A; Dromparis P; Saleme B; Gurtu V; Watson K; Paulin R; Zervopoulos S; Stenson T; Sutendra G; Pink DB; Carmine-Simmen K; Moore R; Lewis JD; Michelakis ED
Eur Urol; 2016 Apr; 69(4):734-744. PubMed ID: 26433571
[TBL] [Abstract][Full Text] [Related]
38. Wild-type IDH1 inhibits the tumor growth through degrading HIF-α in renal cell carcinoma.
Chen S; Wang Y; Xiong Y; Peng T; Lu M; Zhang L; Guo Z
Int J Biol Sci; 2021; 17(5):1250-1262. PubMed ID: 33867843
[TBL] [Abstract][Full Text] [Related]
39. MicroRNA-200b is downregulated and suppresses metastasis by targeting LAMA4 in renal cell carcinoma.
Li Y; Guan B; Liu J; Zhang Z; He S; Zhan Y; Su B; Han H; Zhang X; Wang B; Li X; Zhou L; Zhao W
EBioMedicine; 2019 Jun; 44():439-451. PubMed ID: 31130475
[TBL] [Abstract][Full Text] [Related]
40. Silencing of HIF-1alpha suppresses tumorigenicity of renal cell carcinoma through induction of apoptosis.
Xu K; Ding Q; Fang Z; Zheng J; Gao P; Lu Y; Zhang Y
Cancer Gene Ther; 2010 Mar; 17(3):212-22. PubMed ID: 19816521
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
